{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T04:53:13Z","timestamp":1778561593164,"version":"3.51.4"},"reference-count":51,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics in Dermatology"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1016\/j.clindermatol.2021.04.001","type":"journal-article","created":{"date-parts":[[2021,4,27]],"date-time":"2021-04-27T07:40:46Z","timestamp":1619509246000},"page":"523-531","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":80,"title":["Cutaneous adverse effects of the available COVID-19 vaccines"],"prefix":"10.1016","volume":"39","author":[{"given":"Georgi","family":"Bogdanov","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivan","family":"Bogdanov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jana","family":"Kazandjieva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nikolai","family":"Tsankov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clindermatol.2021.04.001_bib0001","doi-asserted-by":"crossref","DOI":"10.1098\/rstb.2013.0433","article-title":"The contribution of vaccination to global health: past, present and future","volume":"369","author":"Greenwood","year":"2014","journal-title":"Philos Trans R Soc Lond B Biol Sci"},{"key":"10.1016\/j.clindermatol.2021.04.001_bib0002","doi-asserted-by":"crossref","first-page":"238","DOI":"10.4414\/smw.2010.12980","article-title":"Vaccine hypersensitivity\u2013update and overview","volume":"140","author":"Fritsche","year":"2010","journal-title":"Swiss Med Wkly"},{"key":"10.1016\/j.clindermatol.2021.04.001_bib0003","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s40121-020-00300-x","article-title":"Vaccines for SARS-CoV-2: lessons from other coronavirus strains","volume":"9","author":"Padron-Regalado","year":"2020","journal-title":"Infect Dis Ther"},{"key":"10.1016\/j.clindermatol.2021.04.001_bib0004","doi-asserted-by":"crossref","first-page":"221","DOI":"10.3390\/vaccines9030221","article-title":"Allergic reactions to current available COVID-19 vaccinations: pathophysiology, causality, and therapeutic considerations","volume":"9","author":"Kounis","year":"2021","journal-title":"Vaccines"},{"key":"10.1016\/j.clindermatol.2021.04.001_bib0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.biochi.2017.07.016","article-title":"TMPRSS2: a potential target for treatment of influenza virus and coronavirus infections","volume":"142","author":"Shen","year":"2017","journal-title":"Biochimie"},{"key":"10.1016\/j.clindermatol.2021.04.001_bib0006","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.addr.2020.12.008","article-title":"Non-viral COVID-19 vaccine delivery systems","volume":"169","author":"Park","year":"2021","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.clindermatol.2021.04.001_bib0007","doi-asserted-by":"crossref","first-page":"270","DOI":"10.3390\/v13020270","article-title":"Synthetic messenger RNA-based vaccines: from scorn to hype","volume":"13","author":"Pascolo","year":"2021","journal-title":"Viruses"},{"key":"10.1016\/j.clindermatol.2021.04.001_bib0008","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S0140-6736(21)00234-8","article-title":"Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia","volume":"397","author":"Logunov","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.clindermatol.2021.04.001_bib0009","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1016\/S0140-6736(20)32466-1","article-title":"Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2\/3 trial","volume":"396","author":"Ramasamy","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.clindermatol.2021.04.001_bib0010","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/S0140-6736(20)31605-6","article-title":"Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial","volume":"396","author":"Zhu","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.clindermatol.2021.04.001_sbref0011","series-title":"Fenner and White's Medical Virology","first-page":"155","article-title":"Vaccines and vaccination","author":"Burrell","year":"2017"},{"key":"10.1016\/j.clindermatol.2021.04.001_bib0012","unstructured":"Centers for Disease Control and Prevention, Division of Healthcare Quality Promotion (DHQP). Vaccine safety-adjuvants. Available at: https:\/\/www.cdc.gov\/vaccinesafety\/concerns\/adjuvants.html. Last accessed 20th March 2021."},{"key":"10.1016\/j.clindermatol.2021.04.001_bib0013","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.ijwd.2021.01.007","article-title":"The art of prevention: COVID-19 vaccine preparedness for the dermatologist","volume":"7","author":"Rice","year":"2021","journal-title":"Int J Womens Dermatol"},{"key":"10.1016\/j.clindermatol.2021.04.001_bib0014","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clindermatol.2021.04.001_bib0015","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/S1081-1206(10)61024-1","article-title":"Polysorbate 80 in medical products and nonimmunologic anaphylactoid reactions","volume":"95","author":"Coors","year":"2005","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.clindermatol.2021.04.001_bib0016","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1016\/j.jaip.2020.12.047","article-title":"mRNA vaccines to prevent COVID-19 disease and reported allergic reactions: current evidence and suggested approach","volume":"9","author":"Banerji","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.clindermatol.2021.04.001_bib0017","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1111\/cea.12760","article-title":"Immediate-type hypersensitivity to polyethylene glycols: a review","volume":"46","author":"Wenande","year":"2016","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.clindermatol.2021.04.001_bib0018","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1111\/cod.12931","article-title":"Polyethylene glycol as marker for nitrofurazone allergy: 20 years of experience from Turkey","volume":"78","author":"Ozkaya","year":"2018","journal-title":"Contact Dermatitis"},{"key":"10.1016\/j.clindermatol.2021.04.001_bib0019","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1016\/j.jaip.2018.08.033","article-title":"Polyethylene glycol: not just a harmless excipient","volume":"6","author":"Kennard","year":"2018","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.clindermatol.2021.04.001_bib0020","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s13223-016-0172-7","article-title":"Polyethylene glycol as a cause of anaphylaxis","volume":"12","author":"Wylon","year":"2016","journal-title":"Allergy Asthma Clin Immunol"},{"key":"10.1016\/j.clindermatol.2021.04.001_bib0021","doi-asserted-by":"crossref","unstructured":"Kraft M., Renaudin J.M., Ensina L.F., Kleinheinz A., Bil\u00f2 M.B., Scherer Hofmeier K., et\u00a0al. Anaphylaxis to vaccination and polyethylene glycol (PEG): a perspective from the anaphylaxis registry. J Eur Acad Dermatol Venereol. In press. doi:10.1111\/jdv.17327.","DOI":"10.1111\/jdv.17327"},{"key":"10.1016\/j.clindermatol.2021.04.001_bib0022","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1093\/occmed\/kqv072","article-title":"Allergic reaction to polyethylene glycol in a painter","volume":"65","author":"Antolin-Amerigo","year":"2015","journal-title":"Occup Med (Lond)"},{"key":"10.1016\/j.clindermatol.2021.04.001_bib0023","doi-asserted-by":"crossref","first-page":"72","DOI":"10.5414\/ALX02225E","article-title":"Practical recommendations for the allergological risk assessment of the COVID-19 vaccination - a harmonized statement of allergy centers in Germany","volume":"5","author":"Worm","year":"2021","journal-title":"Allergol Select"},{"key":"10.1016\/j.clindermatol.2021.04.001_bib0024","doi-asserted-by":"crossref","first-page":"e230","DOI":"10.1111\/1346-8138.14808","article-title":"Biologic-induced urticaria due to polysorbate 20","volume":"46","author":"Kato","year":"2019","journal-title":"J Dermatol"},{"key":"10.1016\/j.clindermatol.2021.04.001_bib0025","doi-asserted-by":"crossref","first-page":"394","DOI":"10.18176\/jiaci.0109","article-title":"Anaphylaxis due to the excipient polysorbate 80","volume":"26","author":"Palacios Castano","year":"2016","journal-title":"J Investig Allergol Clin Immunol"},{"key":"10.1016\/j.clindermatol.2021.04.001_bib0026","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1016\/j.jaip.2018.12.003","article-title":"Immediate hypersensitivity to polyethylene glycols and polysorbates: more common than we have recognized","volume":"7","author":"Stone","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.clindermatol.2021.04.001_bib0027","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1542\/peds.146.1MA3.236","article-title":"The Association of Antihistamine Administration and delayed presentation for care in pediatric patients admitted with anaphylaxis","volume":"146","author":"Wiley","year":"2020","journal-title":"Pediatrics"},{"key":"10.1016\/j.clindermatol.2021.04.001_bib0028","doi-asserted-by":"crossref","unstructured":"Sokolowska M., Eiwegger T., Ollert M., Torres M.J., Barber D., Del Giacco S., et\u00a0al. EAACI statement on the diagnosis, management and prevention of severe allergic reactions to COVID-19 vaccines [e-pub ahead of print]. Allergy. doi:10.1111\/all.14739. PMID: 33452689. Last accessed 20th March 2021.","DOI":"10.1111\/all.14739"},{"key":"10.1016\/j.clindermatol.2021.04.001_bib0029","doi-asserted-by":"crossref","first-page":"46","DOI":"10.15585\/mmwr.mm7002e1","article-title":"Allergic reactions including anaphylaxis after receipt of the first dose of Pfizer-BioNTech COVID-19 vaccine\u2014United States, December 14-23, 2020","volume":"70","year":"2021","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.clindermatol.2021.04.001_bib0030","series-title":"FDA Presentation and Voting Questions. Food and Drug Administration (FDA) Center for Biologics Evaluation and Research (CBER) 164th Meeting of the Vaccines and Related Biological Products Advisory Committee","year":"2021"},{"key":"10.1016\/j.clindermatol.2021.04.001_bib0031","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1097\/DSS.0000000000000418","article-title":"Delayed-onset nodules secondary to a smooth cohesive 20 mg\/mL hyaluronic acid filler: cause and management","volume":"41","author":"Beleznay","year":"2015","journal-title":"Dermatol Surg"},{"key":"10.1016\/j.clindermatol.2021.04.001_bib0032","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.2310\/6350.2005.31250","article-title":"Adverse reactions to dermal fillers: review","volume":"31","author":"Lowe","year":"2005","journal-title":"Dermatol Surg"},{"key":"10.1016\/j.clindermatol.2021.04.001_bib0033","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1007\/s12026-017-8980-5","article-title":"Autoimmune\/inflammatory syndrome induced by adjuvants-ASIA-related to biomaterials: analysis of 45 cases and comprehensive review of the literature","volume":"66","author":"Alijotas-Reig","year":"2018","journal-title":"Immunol Res"},{"key":"10.1016\/j.clindermatol.2021.04.001_bib0034","doi-asserted-by":"crossref","first-page":"e14644","DOI":"10.1111\/dth.14644","article-title":"Increased risk of late-onset, immune-mediated, adverse reactions related to dermal fillers in patients bearing HLA-B*08 and DRB1*03 haplotypes","volume":"34","author":"Decates","year":"2021","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.clindermatol.2021.04.001_bib0035","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1111\/j.1468-3083.2007.02354.x","article-title":"Delayed immune-mediated adverse effects related to hyaluronic acid and acrylic hydrogel dermal fillers: clinical findings, long-term follow-up and review of the literature","volume":"22","author":"Alijotas-Reig","year":"2008","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.clindermatol.2021.04.001_bib0036","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.jdcr.2021.02.018","article-title":"Oral angiotensin-converting enzyme inhibitors for treatment of delayed inflammatory reaction to dermal hyaluronic acid fillers following COVID-19 vaccination-a model for inhibition of angiotensin II-induced cutaneous inflammation","volume":"10","author":"Munavalli","year":"2021","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.clindermatol.2021.04.001_bib0037","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s40885-020-00147-x","article-title":"The angiotensin-converting enzyme 2 (ACE2) receptor in the prevention and treatment of COVID-19 are distinctly different paradigms","volume":"26","author":"McLachlan","year":"2020","journal-title":"Clin Hypertens"},{"key":"10.1016\/j.clindermatol.2021.04.001_bib0038","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMc2102131","article-title":"Delayed large local reactions to mRNA-1273 vaccine against SARS-CoV-2","volume":"384","author":"Blumenthal","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clindermatol.2021.04.001_bib0039","doi-asserted-by":"crossref","first-page":"n699","DOI":"10.1136\/bmj.n699","article-title":"Covid-19: European countries suspend use of Oxford-AstraZeneca vaccine after reports of blood clots","volume":"372","author":"Wise","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.clindermatol.2021.04.001_bib0040","unstructured":"European Medicine Agency Safety Committee (PRAC). AstraZeneca\u2019s COVID-19 vaccine: EMA finds possible link to very rare cases of unusual blood clots with low blood platelets. Available at: https:\/\/www.ema.europa.eu\/en\/news\/astrazenecas-covid-19-vaccine-ema-finds-possible-link-very-rare-cases-unusual-blood-clots-low-blood#:~:text=EMA%20confirms%20overall%20benefit%2Drisk,COVID%2D19%20Vaccine%20AstraZeneca. Last accessed 20th March 2021."},{"key":"10.1016\/j.clindermatol.2021.04.001_bib0041","unstructured":"European Medicines Agency. COVID-19 vaccine AstraZeneca: benefits still outweigh the risks despite possible link to rare blood clots with low blood platelets. Available at: https:\/\/www.ema.europa.eu\/en\/news\/covid-19-vaccine-astrazeneca-benefits-still-outweigh-risks-despite-possible-link-rare-blood-clots."},{"key":"10.1016\/j.clindermatol.2021.04.001_bib0042","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.clindermatol.2020.06.015","article-title":"Drug-induced cutaneous vasculitis and anticoagulant-related cutaneous adverse reactions: insights in pathogenesis, clinical presentation, and treatment","volume":"38","author":"Guzman","year":"2020","journal-title":"Clin Dermatol"},{"key":"10.1016\/j.clindermatol.2021.04.001_bib0043","doi-asserted-by":"crossref","unstructured":"Pai M., Grill A., Ivers N., Maltsev A., Miller K.J., Razak F., et\u00a0al. Vaccine-induced prothrombotic immune thrombocytopenia (VIPIT) following AstraZeneca COVID-19 vaccination. Available at: https:\/\/doi.org\/10.47326\/ocsat.2021.02.17.1.0.","DOI":"10.47326\/ocsat.2021.02.17.1.0"},{"key":"10.1016\/j.clindermatol.2021.04.001_bib0044","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/S0140-6736(20)31604-4","article-title":"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1\/2, single-blind, randomised controlled trial","volume":"396","author":"Folegatti","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.clindermatol.2021.04.001_bib0045","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0140-6736(20)32661-1","article-title":"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK","volume":"397","author":"Voysey","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.clindermatol.2021.04.001_bib0046","series-title":"Suspected delayed inflammatory cutaneous reaction after ChAdOx1 nCoV-19 vaccine located in preexisting morphea lesions","author":"Bogdanov","year":"2021"},{"key":"10.1016\/j.clindermatol.2021.04.001_bib0047","doi-asserted-by":"crossref","unstructured":"Sadoff J., Le Gars M., Shukarev G., Heerwegh D., Truyers C., de Groot A.M., et\u00a0al. Interim results of a phase 1-2a trial of Ad26.COV2.S covid-19 vaccine [e-pub ahead of print]. N Engl J Med. doi:10.1056\/NEJMoa2034201.","DOI":"10.1056\/NEJMoa2034201"},{"key":"10.1016\/j.clindermatol.2021.04.001_bib0048","unstructured":"Marks P., Schuchat A. Joint CDC and FDA statement on Johnson & Johnson COVID-19 vaccine. Available at: https:\/\/www.fda.gov\/news-events\/press-announcements\/joint-cdc-and-fda-statement-johnson-johnson-covid-19-vaccine."},{"key":"10.1016\/j.clindermatol.2021.04.001_bib0049","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1080\/17474086.2019.1636645","article-title":"High-dose intravenous immunoglobulin for the treatment and prevention of heparin-induced thrombocytopenia: a review","volume":"12","author":"Warkentin","year":"2019","journal-title":"Expert Rev Hematol"},{"key":"10.1016\/j.clindermatol.2021.04.001_bib0050","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/S0140-6736(20)31866-3","article-title":"Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1\/2 studies from Russia","volume":"396","author":"Logunov","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.clindermatol.2021.04.001_bib0051","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1016\/S0140-6736(20)31208-3","article-title":"Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial","volume":"395","author":"Zhu","year":"2020","journal-title":"Lancet"}],"container-title":["Clinics in Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0738081X21000614?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0738081X21000614?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:19:04Z","timestamp":1760033944000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0738081X21000614"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":51,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["S0738081X21000614"],"URL":"https:\/\/doi.org\/10.1016\/j.clindermatol.2021.04.001","relation":{},"ISSN":["0738-081X"],"issn-type":[{"value":"0738-081X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cutaneous adverse effects of the available COVID-19 vaccines","name":"articletitle","label":"Article Title"},{"value":"Clinics in Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clindermatol.2021.04.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}